Table 1.
Baseline Clinical Demographics (N=101)
| Age, y | 72 (61–77) |
| Men, n (%) | 80 (79) |
| BMI, kg/m2 | 23±3 |
| Hypertension, n (%) | 69 (68) |
| Diabetes mellitus, n (%) | 49 (49) |
| Dyslipidemia, n (%) | 51 (50) |
| Chronic kidney disease, n (%) | 32 (32) |
| Smoking, n (%) | 27 (27) |
| History of myocardial infarction, n (%) | 6 (6) |
| History of stroke, n (%) | 5 (5) |
| History of PAD, n (%) | 4 (4) |
| CAD type, n (%) | |
| Acute coronary syndrome | 71 (70) |
| Stable CAD | 30 (30) |
| Multivessel disease | 44 (45) |
| Biochemistry data | |
| Glycated hemoglobin, % | 5.9 (5.6–6.3) |
| eGFR, mL/min per 1.73m2 | 68±21 |
| Systolic BP, mm Hg | 124±18 |
| Diastolic BP, mm Hg | 71±14 |
| Baseline medication use, n (%) | |
| Aspirin | 7 (7) |
| ACEI/ARB | 18 (18) |
| β‐Blocker | 10 (9) |
| Concomitant medications use | |
| Lipid‐lowering therapy, n (%) | |
| Statin | 101 (100) |
| Rosuvastatin | 77 (76) |
| Pitavastatin | 16 (16) |
| Atorvastatin | 8 (8) |
| High‐intensity statin use* | 55 (54) |
| Other established medication, n (%) | |
| Aspirin | 89 (88) |
| Clopidogrel | 27 (27) |
| Prasugrel | 55 (54) |
| ACEI/ARB | 66 (65) |
| β‐Blocker | 55 (54) |
Continuous variables are expressed as mean±SD, and non‐normally distributed continuous data are summarized as median (interquartile range).
ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blockers; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; and PAD, peripheral arterial disease.
*
Rosuvastatin ≥10 mg, pitavastatin ≥4 mg, and atorvastatin ≥20 mg.